Atopic Dermatitis Drug Market Sales Statistics, Cost, Size Estimation and Share Growth Analysis By 2026 | Bayer Healthcare, Valent Pharmaceutical Inc., Astellas Pharma Inc., Meda AB, and Novartis AG.
Atopic dermatitis is referred to as eczema, it is a medical condition in which skin becomes dry, itchy, and inflamed, and can leads to redness, swelling, scaling, and crusting. Atopic dermatitis commonly occurs in children under one year. The dry climate is a major cause of atopic dermatitis. This disease is non-contagious and easily diagnosed with signs and symptoms such as swelling and redness of the skin. Moreover, many people with atopic dermatitis also develop asthma and hay fever. It can be treated by using phototherapy, steroid pills, calcineurin inhibitors ointment, biologic agents such as immunologic, monoclonal antibody, and dietary changes in case of food allergy.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/712
By End User
- Research Labs
By Route of Administration
- Photo Therapy
- Directed Therapy
Quick Buy – Atopic Dermatitis Drug Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/712
Topical steroids and development of new drugs is expected to fuel the atopic dermatitis drug market growth
Atopic dermatitis treatment majorly depends on topical steroids and therefore the segment holds the largest market share. A lukewarm bath followed by the usage of moisturizers is useful in the treatment of atopic dermatitis. Moreover, immunomodulators and pimecrolimus are also used for the treatment of atopic dermatitis. According to the American Academy of Dermatology, in 2016, there were around 28 million people of all age groups affected by atopic dermatitis in the U.S. The expected launch of dupilumab, monoclonal antibody developed by Sanofi and Regeneron Pharmaceuticals Inc. in 2017, which is approved by FDA for the treatment of atopic dermatitis plays a major role in the treatment of the disease and supports the growth of atopic dermatitis drug market. In December 2016, the crisaborole ointment was approved by the FDA for the treatment of mild atopic dermatitis. When such drugs are launched, FDA issues black box warning on the label of prescribed drug to warn users about the side effects. However, the side effects of the drug and the high cost of treatment are expected to hinder market growth.
Developed regions support the growth of atopic dermatitis drug market
On the basis of geography, the global atopic dermatitis drug market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the atopic dermatitis drug market owing to the growing number of atopic dermatitis cases and high R&D investment for the development of atopic dermatitis drug. Europe is the second-largest market for atopic dermatitis drugs followed by the Asia Pacific. The Asia Pacific is a flourishing market due to the high prevalence of atopic dermatitis and increased demand for drugs across emerging countries such as India and China.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/atopic-dermatitis-drug-market-712
Major players in the market use different strategies such as mergers and acquisitions in order to acquire a high market share and attain a competitive edge. In 2016, Novartis AG acquired Ziarco, which adds oral atopic dermatitis drug to its product pipeline. Pfizer acquired Anacor Pharmaceuticals in 2016 allowing access to non-steroidal topical gel, crisaborole, approved by FDA for atopic dermatitis treatment. Some of the key players in the market are Bayer Healthcare, Valent Pharmaceutical Inc., Astellas Pharma Inc., Meda AB, and Novartis AG.
Table of Content
Global Atopic Dermatitis Drug Market Research Report
Section 1: Global Atopic Dermatitis Drug Industry Overview
Section 2: Global Economic Impact on Atopic Dermatitis Drug Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Atopic Dermatitis Drug Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Atopic Dermatitis Drug Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire